Clinical Trials

Breast Neoplasms, Neoplasms

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

7 enrolled

Genitourinary

Prostatic Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

23 enrolled 10 charts

Breast Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Phase 3 Completed

446 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

226 enrolled

Breast Neoplasms

NCT07115095 2025-08-11

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Phase NA Completed

98 enrolled

HER2-positive Breast Cancer

NCT02252887 2025-07-25

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

45 enrolled

Metastatic HER2-Positive Breast Cancer

NCT01817452 2025-02-26

ADAPT

220 enrolled

Breast Neoplasms

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02339532 2024-11-08

NeoTOP

86 enrolled

Breast Neoplasms

NCT05572645 2024-02-26

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Completed

333 enrolled

Breast Neoplasms

NCT03845270 2023-12-19

R2D2

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03988036 2023-05-15

Keyriched-1

46 enrolled

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01922921 2023-04-18

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

31 enrolled 8 charts

Breast Neoplasms

NCT02789657 2022-05-19

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

32 enrolled 10 charts

Breast Neoplasms

NCT01847001 2021-09-10

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

10 enrolled 12 charts

Breast Neoplasms

NCT03135171 2021-09-10

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Phase 1 Completed

11 enrolled

Breast Neoplasms

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

208 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02139358 2021-02-04

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

15 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02682693 2021-02-02

GeparX

780 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01875666 2020-09-04

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

26 enrolled

Breast Neoplasms

NCT02581462 2020-08-11

PETRARCA

Phase 2/3 Completed

81 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01276041 2020-08-03

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

70 enrolled 11 charts

Breast Neoplasms

NCT02530424 2020-07-15

NA-PHER2

102 enrolled

Breast Neoplasms

NCT02120911 2020-07-01

TRAP

40 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01855828 2020-03-31

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

50 enrolled 13 charts

Her2-Positive Breast Cancer

NCT01959490 2019-03-05

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

16 enrolled 8 charts

Breast Neoplasms

NCT02411344 2018-09-18

PER-ELISA

64 enrolled

Breast Neoplasms

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1 Completed

9 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase 3 Completed

961 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

43 enrolled 9 charts

Endocrine

Carcinoma, Neuroendocrine

NCT01048099 2016-01-29

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Phase NA Completed

283 enrolled 8 charts